Glaukos earnings ahead as new drug launch tests growth trajectory By Investing.com

Glaukos is expected to report Q1 revenue of $137.0 million and an EPS loss of $0.28, with revenue still projected to grow 28% year over year despite a sequential decline from Q4's $143.1 million. Investors are focused on iDose TR momentum, early adoption of Epioxa, and whether the company can progress toward cash-flow breakeven in 2026 amid heavy launch spending. Analyst expectations remain constructive, with all 13 analysts rating the stock Strong Buy and a mean target of $138.92, about 16% above the current share price.

Analysis

GKOS is becoming a classic “good product, hard math” story: the market is no longer rewarding top-line acceleration alone, it needs proof that incremental dollars from iDose TR and Epioxa convert into operating leverage. The setup is asymmetric because any evidence that commercial spending is normalizing could re-rate the stock sharply, but another disappointment on margins would likely compress it further given the stretched loss multiple and the market’s sensitivity to unprofitable growth names.

The bigger second-order issue is channel mix. iDose TR’s scaling should eventually improve lifetime value economics, but the real near-term swing factor is Epioxa adoption friction: if payor coverage lags, the company absorbs launch costs while legacy franchise revenue erodes, creating a temporary margin trough. The permanent J-code is important less as a headline and more as a catalyst that can shorten reimbursement cycle times; that should reduce working capital drag and may accelerate repeat utilization if physician offices see cleaner payment behavior.

Consensus appears to assume a smooth transition from launch investment to profitability, but that is likely too linear. A better framing is that GKOS has a 2-3 quarter window where gross profit growth can outrun opex growth; if not, the stock will behave like a development-stage biotech rather than a scaled medtech platform. The key contrarian risk is that management may choose to lean harder into direct-to-consumer and field-force expansion precisely when investors want discipline, which could keep losses elevated even as revenue remains healthy.

Key Decisions for Investors

• Trade the event: buy GKOS straddles into earnings only if implied move remains below 8-10%; the stock’s near-term path is likely driven by margin commentary more than revenue, creating convexity if opex surprises either way.
• If holding cash equity, prefer a post-print entry on GKOS only on confirmation of payor traction for Epioxa; downside risk is another 10-15% drawdown if launch economics look noisy, while upside on credible margin inflection can be 15-20% over 1-2 quarters.
• Pair trade: long GKOS / short another high-growth, high-spend medtech name with weaker reimbursement visibility over the next 1-2 quarters; GKOS has a clearer path to monetizing recent launches if coverage adoption improves.
• For more tactical traders, take profits on any earnings gap-up unless management raises 2026 margin trajectory; the market is likely to reward proof of operating leverage more than incremental revenue beats.